People in the News

Jun 22, 2017

David Daly

Foundation Medicine has announced that David Daly intends to resign for personal reasons effective August 11. Daly currently serves as chief commercial officer and general manager of clinical oncology solutions for the company. No replacement has yet been named.

Jun 22, 2017

Flemming Ornskov

Waters has appointed Flemming Ornskov to its board of directors. Ornskov currently serves as CEO of Shire, where he also serves as chairman of the executive committee and as a member of its board of directors. He has also held key executive leadership positions at Bayer, Bausch & Lomb, Merck, and Novartis.

Jun 22, 2017

Mara Aspinall

OraSure Technologies has appointed Mara Aspinall to its board of directors. Aspinall currently serves as the president and CEO of Health Catalysts. She also serves as the executive chairman of GenePeeks. Prior to these positions, Aspinall served as president, CEO and global head of Roche Tissue Diagnostics. She also founded and served as CEO and director of On-Q-ity, served as president of Genzyme Genetics, served as president of the Genzyme Pharmaceuticals.

Jun 21, 2017

Philippe Goix

Avant Diagnostics has appointed Philippe Goix as president and CEO. Goix comes to Avant from Prism Health Diagnostics where he served as president, CEO, and co-founder. Before his time at Prism Health, he consulted for several healthcare companies, and has also served as president and CEO of Singulex, and president and CEO of Guava Technologies, now part of Merck Millipore.

Jun 21, 2017

Peter Meintjes

Omixon has appointed Peter Meintjes as CEO. Meintjes replaces current CEO Tim Hague who will step into a consultancy role and remains a shareholder of the company. Most recently, Meintjes served as chief commercial officer at Omixon. He joined the company in 2014.

Jun 16, 2017

Kieran Murphy

GE Healthcare has appointed Kieran Murphy as president and CEO. He succeeds John Flannery, who has been appointed CEO and chairman elect of GE. Murphy was appointed CEO of GE Healthcare Life Sciences in September 2011, and he joined GE Healthcare in 2008 from Whatman. He has also held leadership roles at Mallinckrodt, Novartis, Adprotech, ML Laboratories, and Innovata.

Jun 15, 2017

Robert Green, Natasha Frank

Veritas Genetics has appointed Robert Green and Natasha Frank to its medical and scientific advisory board. Green directs the Genomes2People research program. He also leads the first randomized trials to explore the implementation of medical sequencing in adults and newborns through the MedSeq and BabySeq projects. Frank leads research programs funded by the US National Institutes of Health, Veterans Administration, and the Department of Defense that investigate the biology of stem cells residing in human tissues and their relationship to genetic disease and cancer.

Jun 15, 2017

Sean Freeman

Molecular Assemblies has appointed Sean Freeman to its board of directors. Freeman currently serves as head of strategy and corporate development at NuVasive. He previously served as senior VP of business development for Cole-Parmer Instrument, and as head of corporate ventures and M&A at Life Technologies, which was later acquired by Thermo Fisher Scientific. He has also worked as an investment banker in Merrill Lynch's mergers & acquisitions group.

Jun 07, 2017

Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis

Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.

Jun 05, 2017

Joris Veltman

Joris Veltman has taken the position of director of the Institute of Genetic Medicine at Newcastle University in the UK. He previously served as a professor of translational genomics in the department of human genetics at Radboud University Medical Centre in Nijmegen in the Netherlands, with a joint appointment in the department of clinical genetics at Maastricht University Medical Centre.

Jun 02, 2017

Howard McLeod

Viviphi has appointed Howard McLeod to its precision medicine advisory board, and has named him senior research advisor in precision medicine. McLeod previously served in leadership positions at the H. Lee Moffitt Cancer Center's Department of Individualized Cancer Management. He also served as an endowed research chair in the state of Florida, professor at the University of South Florida, and serves as a 1000 Talent Scholar in China. Additionally, he has served on the FDA's committee on clinical pharmacology and on the National Institutes of Health's Human Genome Advisory Council.

Jun 01, 2017

Shelly Guyer

Invitae has appointed Shelly Guyer as its CFO, effective June 12. She will also serve as the company's principal financial officer. Invitae's current CFO Lee Bendekgey will fully transition to his new role as COO. Most recently, Guyer served as CFO of Veracyte. 

May 31, 2017

Mona Miller

The American Society of Human Genetics has appointed Mona Miller as executive director. She will be responsible for representing the ASHG on a day-to-day basis, for guiding and implementing its broad agenda in consultation with the president and board, and for interacting on an ongoing basis with society committees. Miller currently serves as the deputy executive director for programs and finance at the Society for Neuroscience. She has previously served as the society's senior director of communications and public affairs, the senior officer of public affairs at the Pew Charitable Trusts, and as communications director to former Senator Barbara Mikulski.

May 25, 2017

Saturnino Fanlo

Human Longevity has appointed Saturnino Fanlo as CFO. Fanlo will report to CEO Cynthia Collins. He joins Human Longevity from Social Finance (SoFi), where he served as president and CFO. Prior to SoFi, Fanlo held a series of high level leadership roles in various financial firms, including senior advisor at Golden Gate Capital, CEO at KKR Financial, chief information officer at KKR Asset Management, and executive VP and treasurer at Wells Fargo. He has also held positions with Goldman Sachs, Australian Capital Equity, and First Boston Corporation.

May 25, 2017

Andrea Califano

Tempus has appointed Andrea Califano to its scientific advisory board. Califano serves as the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is also the founding chair of the department of systems biology, director of the JP Sulzberger Columbia Genome Center, and associate director for bioinformatics at the Herbert Irving Comprehensive Cancer Center. Additionally, he holds appointments in the department of biochemistry and molecular biophysics and the department of biomedical informatics.

May 25, 2017

Jay Flatley

Juno Therapeutics has appointed Jay Flatley to its board of directors. He currently serves as executive chairman of Illumina and as the chair for the board of directors of Illumina's subsidiary, Helix. He also serves an advisory board member for UC San Diego's Moore Cancer Center, serves as the board of directors at Coherent and Denali, and is on the board of trustees of the Salk Institute. Previously, he served as CEO of Illumina from 1999 to 2016.  Before Illumina, he served as president and CEO of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare.

May 22, 2017

Mark Van Oene

Illumina has named Mark Van Oene chief commercial officer. He will be responsible for worldwide sales, services, and marketing and will report to CEO Francis deSouza. Van Oene previously served as Illumina's senior vice president of the Americas region and has served as interim CCO since late 2016. He joined Illumina in 2006 as regional account manager for Canada.

May 18, 2017

Don Hardison

Biotheranostics has appointed Don Hardison as CEO, succeeding Nicolas Barthelemy. Hardison originally joined Biotheranostics in July 2016 as part of its board of directors. Most recently, he served as president, CEO, and director of Good Start Genetics. He has also served as CEO of Exact Sciences and held senior leadership roles at Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham.

May 17, 2017

Stanley Lapidus

Aushon BioSystem has appointed Stanley Lapidus to its board of directors. He brings more than three decades of experience founding and leading breakthrough diagnostic companies. Lapidus founded and served as CEO for Cytyc, now part of Hologic, in the late 80's.  After Cytic, he founded Exact Sciences where he served as CEO until 2001 and chairman until 2005. He also was both founder and CEO of SynapDx and Helicos Biosciences.

May 17, 2017

John Marshall

Caris Life Sciences has appointed John Marshall as its chief medical officer. In this role, Marshall will direct the company's oncology research efforts, guide clinical strategies for innovative precision medicine and tumor profiling services, and continue to serve as chairman of the Caris Centers of Excellence for Precision Medicine Network. He currently serves as associate director for clinical care at the Georgetown Lombardi and chief of the division of hematology-oncology at MedStar Georgetown University Hospital. Marshall is also the founding director of Georgetown Lombardi's Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer.

May 15, 2017

Wendy Rubinstein

Wendy Rubinstein has been named the first division director for clinical data management and curation of CancerLinQ, a nonprofit subsidiary of the American College of Clinical Oncology. In this newly created role, Rubinstein will lead all clinical data quality and data curation at CancerLinQ. Rubinstein previously served as chief of medical genetics and human variation at the NIH National Center for Biotechnology Information, director of the NIH Genetic Testing Registry, and in various leadership positions at NorthShore University HealthSystem in Evanston, Illinois.

May 11, 2017

Jeffrey Edwards, Arnold Pinkston, Gregory Hinckley

Bio-Rad has elected three new board members — Jeffrey Edwards, Gregory Hinckley, and Arnold Pinkston — at its annual shareholders meeting. 

Jeffrey Edwards previously served as CEO of Allergan from 2005 to August 2014, and retired from the company in 2015 after 22 years

Arnold Pinkston previously served as executive vice president and general counsel for Allergan, senior vice president and general counsel for Beckman Coulter, and vice president and deputy general counsel at Eli Lilly.

Gregory Hinckley currently serves as president of Mentor Graphics, a supplier of products and services used for the design of electronic content, and has 30 years of public company experience.

The newly-elected members replace Louis Drapeau, Robert Malchione, Joel McComb and Deborah Neff, who declined to stand for reelection due to disagreements with Bio-Rad's management regarding executive personnel and corporate governance matters, according to a Securities and Exchange Commission filing. In a statement, Bio-Rad noted that their decision not to stand for reelection was not related to any issues regarding the integrity of the company's financial statements or accounting policies and practices.

May 11, 2017

Steven Sepulveda

Mesa Biotech has appointed Steven Sepulveda vice president of global business development and channel management. Sepulveda will be responsible for directing and overseeing all aspects of commercial global sales, business development, strategic alliances, and distributor relationship management. He has 26 years of experience in the IVD business with companies such as Quidel, Beckman Coulter, and Sekisui Diagnostics.

May 11, 2017

John Kraeutler

John Kraeutler will retire as CEO from Meridian Bioscience as part of a planned transition as soon as the firm finds his successor. He will remain as executive chairman of Meridian's board of directors and will be available to assist the new CEO during the transition and onboarding phase, the firm said in a statement. Kraeutler joined the company as CEO in 1992.

May 11, 2017

Madhuri Hegde

PerkinElmer has appointed Madhuri Hegde as VP and chief scientific officer for its newly created Laboratory Services group. In this role, Hegde will oversee the laboratory services group to ensure the delivery of innovative solution to clinical and healthcare system customers, the company said. She joins PerkinElmer from Emory Genetics Lab where she served as chief scientific officer and executive director.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.